PT  - JOURNAL ARTICLE
AU - BASIL+ trial collective
AU  - Burke, Lauren
AU  - Littlewood, Elizabeth
AU  - Gascoyne, Samantha
AU  - McMillan, Dean
AU  - Chew-Graham, Carolyn A.
AU  - Bailey, Della
AU  - Sloan, Claire
AU  - Fairhurst, Caroline
AU  - Baird, Kalpita
AU  - Hewitt, Catherine
AU  - Henry, Andrew
AU  - Ryde, Eloise
AU  - Shearsmith, Leanne
AU  - Coventry, Peter
AU  - Crosland, Suzanne
AU  - Newbronner, Elizabeth
AU  - Traviss-Turner, Gemma
AU  - Woodhouse, Rebecca
AU  - Clegg, Andrew
AU  - Gentry, Tom
AU  - Hill, Andrew
AU  - Lovell, Karina
AU  - Smith, Sarah Dexter
AU  - Webster, Judith
AU  - Ekers, David
AU  - Gilbody, Simon
TI  - Behavioural Activation for Social IsoLation (BASIL<sup>+</sup>) trial (Behavioural activation to mitigate depression and loneliness among older people with long-term conditions): Protocol for a fully-powered pragmatic randomised controlled trial
AID  - 10.1101/2022.01.29.22270065
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.29.22270065
4099  - http://medrxiv.org/content/early/2022/02/01/2022.01.29.22270065.short
4100  - http://medrxiv.org/content/early/2022/02/01/2022.01.29.22270065.full
AB  - Introduction Depression is a leading mental health problem worldwide. People with long-term conditions are at increased risk of experiencing depression. The COVID-19 pandemic led to strict social restrictions being imposed across the UK population. Social isolation can have negative consequences on the physical and mental wellbeing of older adults. In the Behavioural Activation in Social IsoLation (BASIL+) trial we will test whether a brief psychological intervention (based on Behavioural Activation), delivered remotely, can mitigate depression and loneliness in older adults with long-term conditions during isolation.Methods We will conduct a two-arm, parallel-group, randomised controlled trial across several research sites, to evaluate the clinical and cost-effectiveness of the BASIL+ intervention. Participants will be recruited via participating general practices across England and Wales. Participants must be aged ≥65 with two or more long-term conditions, or a condition that may indicate they are within a ‘clinically extremely vulnerable’ group in relation to COVID-19, and have scored ≥5 on the Patient Health Questionnaire (PHQ9), to be eligible for inclusion. Randomisation will be 1:1, stratified by research site. Intervention participants will receive up to eight intervention sessions delivered remotely by trained BASIL+ Support Workers and supported by a self-help booklet. Control participants will receive usual care, with additional signposting to reputable sources of self-help and information, including advice on keeping mentally and physically well.A qualitative process evaluation will also be undertaken to explore the acceptability of the BASIL+ intervention, as well as barriers and enablers to integrating the intervention into participants’ existing health and care support, and the impact of the intervention on participants’ mood and general wellbeing in the context of the COVID-19 restrictions. Semi-structured interviews will be conducted with intervention participants, participant’s caregivers/supportive others and BASIL+ Support Workers.Outcome data will be collected at one, three, and 12 months post-randomisation. Clinical and cost-effectiveness will be evaluated. The primary outcome is depressive symptoms at the three-month follow up, measured by the PHQ9. Secondary outcomes include loneliness, social isolation, anxiety, quality of life, and a bespoke health services use questionnaire.Discussion This study is the first large-scale trial evaluating a brief Behavioural Activation intervention in this population, and builds upon the results of a successful external pilot trial.Trial Registration ClinicalTrials.Gov identifier ISRCTN63034289, registered on 5th February 2021.Funding This study was funded by National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) RP-PG-0217-20006Competing Interest StatementWe have read the journal?s policy and the authors of this manuscript have the following competing interests. DE and CCG are current committee members for the NICE Depression Guideline (update) Development Group, and SG was a member between 2015-18. SG, PC and DMcM are supported by the NIHR Yorkshire and Humberside Applied Research Collaboration (ARC) and DE is supported by the North East and North Cumbria ARCs.Clinical TrialClinicalTrials.Gov identifier ISRCTN63034289, registered on 5th February 2021.Funding StatementEL, DM, CCG, CH, PC, GTT, AC, TG, AH, KL, SDS, DE and SG were funded by National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) RP-PG-0217-20006. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial received ethical approval from Yorkshire and The Humber - Leeds West Research Ethics Committee on 11 December 2021 (REC Ref: 20/YH/0347). The sponsor for BASIL+ is Tees, Esk and Wear Valleys NHS Foundation Trust.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.